Frelii (FRLI) Stock Price

Frelii Price

OTC·CLOSED
0.00
​
Market closed

Revenue at Frelii has contracted by 18.6% per year over the past 9 years to 35,945.00 USD. For Frelii, the net margin of -15,439.4% is down versus 69.6% a few years ago.

Frelii stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Frelii business model & stock analysis

Frelii Inc is an emerging company in the field of personalized healthcare and diagnostics. The company, which opened its headquarters in Salt Lake City, Utah, USA in 2016, aims to provide personalized therapies and diagnoses for each patient based on DNA tests and computer analysis. The company has a specialized team of scientists, doctors, engineers, and IT experts who have come together to develop advanced technologies that have the potential to revolutionize healthcare. Business model: Frelii's business model is focused on providing personalized diagnoses and therapies for each patient. The company can achieve this through a combination of DNA testing, genome data analysis, and the use of AI algorithms. With a wide range of tests and analyses, Frelii can unleash the full potential of high-tech diagnostics and minimally invasive therapy. History: The company was founded by CEO Ian Jenkins and Dr. David R. Koepsell (formerly President of Upturn). Their goal was to decipher the human genome and use the results of genome tests to provide precise diagnoses and therapies. Since then, the company has focused on understanding the complexity of the human genome and maximizing the capabilities of personalized medicine and diagnostics. Offered divisions and products: Frelii offers a range of personalized DNA tests and analyses. These tests examine an individual's entire genome to gain information about personal risks for diseases, allergies, and other medical conditions. These results are then analyzed by a team of scientists and doctors who create personalized recommendations for diet, lifestyle, and medical therapy. Frelii also has its own software platform for processing genome data and offers personalized research and development programs for clinical studies, association analyses, and genome-wide screens. The company is also a leader in the development of therapy and diagnostic methods based on CRISPR/Cas9 and other high-tech technologies. The Frelii team is committed to improving the quality of medical care and facilitating access to personalized healthcare methods. Frelii's DNA tests have already led to a variety of patients being able to discover their disease risks for themselves and consciously engage in adapting their lifestyles. The company aims to bring research efforts and the practical implementation of personalized medicine to the forefront. Conclusion: Frelii is at the forefront of personalized genomic research and aims to take healthcare to a whole new level. The company offers personalized DNA tests and analyses, as well as the analysis of genome data to provide precise diagnoses and therapies. Frelii has its own software platform for processing genome data that engages medical researchers, doctors, and patients alike. It remains to be seen how this emerging company will redefine personalized medical care.

Frequently asked questions about Frelii

Frelii Inc operates under a unique business model that combines advanced genetics, artificial intelligence, and big data analytics. The company focuses on providing personalized precision medicine and healthcare solutions to individuals. Frelii utilizes its proprietary DNA sequencing platform to uncover genetic insights and form comprehensive health profiles. By leveraging the power of AI and vast amounts of data, Frelii analyzes this information to offer tailored treatment plans, preventive measures, and lifestyle recommendations. This innovative approach enables individuals to make informed decisions about their health and well-being, improving overall outcomes. Frelii Inc's business model seamlessly integrates cutting-edge technology with the realm of healthcare to deliver personalized and optimized solutions.

Frelii Inc is primarily active in the biotechnology industry.

The main competitors of Frelii Inc in the market include companies like 23andMe, Ancestry.com, and MyHeritage.

Frelii Inc is a leading company in the field of personalized health and wellness solutions. Established in [year], Frelii has a rich history of innovation and breakthroughs in the healthcare industry. The company focuses on utilizing advanced genetic sequencing and AI technology to develop personalized treatment plans for individuals, revolutionizing the way healthcare is delivered. Frelii's commitment to research and development has led to numerous partnerships and collaborations with renowned institutions and experts in the field. The company's dedication to providing cutting-edge healthcare solutions has positioned Frelii Inc as a trusted name in the industry. With its extensive expertise and forward-thinking approach, Frelii continues to pave the way for a healthier future.

Frelii Inc, a leading company in the field of personalized health sciences, has achieved several significant milestones. The company successfully launched its revolutionary AI-powered genomic sequencing platform, empowering individuals with actionable health insights and personalized treatment options. Frelii Inc has also secured strategic partnerships with prominent healthcare organizations, enabling them to expand their reach and accelerate the adoption of their advanced genetic testing solutions. Furthermore, the company has received prestigious awards and recognition for its groundbreaking contributions to the healthcare industry. Frelii Inc continues to pioneer innovative advancements in personalized medicines, positively impacting the lives of countless individuals worldwide.

Frelii Inc is primarily present in the United States.

Frelii Inc represents a set of values and a corporate philosophy focused on the advancement of personalized medicine and genetic testing. With their cutting-edge technology and comprehensive DNA analysis, they strive to empower individuals to make informed healthcare decisions. Frelii Inc is committed to enhancing the health and well-being of their customers by providing accurate genetic insights and tailored solutions. They prioritize scientific rigor, data privacy, and ethical practices, ensuring the utmost care for their customers' genetic information. Frelii Inc aims to pioneer breakthroughs in personalized healthcare, revolutionizing the way we diagnose, prevent, and treat diseases.

Converted at the current exchange rate, the Frelii share trades at 0.00 EUR (0.00 USD).

Frelii Inc. is an American company based in Utah that was founded in 2017. It is a leading company in the field of genome analysis and DNA testing, providing customized solutions for their customers' health needs. The company utilizes cutting-edge technology and expertise to develop DNA tests that are capable of providing disease-preventive and predictive information. Frelii Inc. offers three different divisions tailored to the needs of their customers. These divisions include Frelii Health, Frelii DNA, and Frelii Genomic Research. Each division focuses on a specific area of genome analysis to provide specialized solutions for their customers' needs. Frelii Health is the first division of the company, offering individuals and families personalized DNA tests for improved health conditions. Frelii Health focuses on improving the health and well-being of their customers by providing genetic information for personalized nutrition, personalized fitness programs, personalized lifestyle advice, and more. Frelii DNA is the second division of the company, focusing on analyzing an individual's DNA to understand their traits and behaviors. The division suggests personalized solutions for everyday use and is an important tool for customers who have health-related questions related to their DNA. Frelii DNA also provides a simple method for storing DNA samples so that they can be analyzed when needed. Frelii Genomic Research is the third division of the company, focusing on DNA research that helps the company leverage the latest developments and innovations in genomics to improve their genetic tests and solutions. Frelii Genomic Research also provides cloud-based platforms for scientists and researchers from around the world to access genetic information and collaborate on it. Frelii Inc. also offers a wide range of products that customers can choose to use. These products include DNA test kits that are delivered directly to the user's home to enable quick and easy analysis of DNA samples. Additionally, the company offers a range of personalized nutrition, fitness, and lifestyle solutions to enable their customers to lead better lives. Overall, Frelii Inc. provides their customers with personalized and tailored genetic solutions to achieve a better understanding of their DNA and genetic profiles. The company utilizes cutting-edge technology and research to develop genetic tests and solutions that lead to a healthier and more productive lifestyle. With its various divisions and products, Frelii Inc. is committed to customer-oriented and innovative solutions, leading the company into the future of genomics and DNA analysis.

The revenue cannot currently be calculated for Frelii.

The profit cannot currently be calculated for Frelii.

The P/E ratio cannot be calculated for Frelii at the moment.

The P/S cannot be calculated for Frelii currently.

The Eulerpool Quality Score for Frelii is 4/10.

The ISIN of Frelii is US3570511010. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Frelii is A2JF9P. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Frelii is FRLI. The ticker symbol is used to trade Frelii shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Technology
Number of shares
Employees
Revenue per Employee
17,972.50 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website frelii.com
Currency
USD
Initial public offering
Jan 18, 2005
ISIN
US3570511010
Cusip
357051101
Sedol
BFZ1DR0
Market capitalization
5,347.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.02
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-2,419.37 %
Last updated Nov 6, 2026, 1:12 AM

Frelii Ticker

OTC · FRLI

Frelii FIGI

FRLI:US · BBG000QP5SJ8FRLI:PQ · BBG000QP5ZW7FRLI:UV · BBG000QP61B4

All fundamentals and in-depth analysis of Frelii

Our stock analysis for Frelii stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Frelii. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.